School of Computer Science and Technology,Xidian University, 710126 Xi'an, Shaanxi, China.
State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, 519020 Macau, China.
Brief Bioinform. 2024 Mar 27;25(3). doi: 10.1093/bib/bbae153.
Predicting the drug response of cancer cell lines is crucial for advancing personalized cancer treatment, yet remains challenging due to tumor heterogeneity and individual diversity. In this study, we present a deep learning-based framework named Deep neural network Integrating Prior Knowledge (DIPK) (DIPK), which adopts self-supervised techniques to integrate multiple valuable information, including gene interaction relationships, gene expression profiles and molecular topologies, to enhance prediction accuracy and robustness. We demonstrated the superior performance of DIPK compared to existing methods on both known and novel cells and drugs, underscoring the importance of gene interaction relationships in drug response prediction. In addition, DIPK extends its applicability to single-cell RNA sequencing data, showcasing its capability for single-cell-level response prediction and cell identification. Further, we assess the applicability of DIPK on clinical data. DIPK accurately predicted a higher response to paclitaxel in the pathological complete response (pCR) group compared to the residual disease group, affirming the better response of the pCR group to the chemotherapy compound. We believe that the integration of DIPK into clinical decision-making processes has the potential to enhance individualized treatment strategies for cancer patients.
预测癌细胞系的药物反应对于推进个性化癌症治疗至关重要,但由于肿瘤异质性和个体差异,这仍然具有挑战性。在这项研究中,我们提出了一种基于深度学习的框架,名为 Deep neural network Integrating Prior Knowledge (DIPK)(DIPK),它采用自监督技术来整合多种有价值的信息,包括基因相互作用关系、基因表达谱和分子拓扑结构,以提高预测准确性和鲁棒性。我们证明了 DIPK 在已知和新的细胞和药物上的性能优于现有方法,强调了基因相互作用关系在药物反应预测中的重要性。此外,DIPK 将其适用性扩展到单细胞 RNA 测序数据,展示了其在单细胞水平反应预测和细胞识别方面的能力。此外,我们还评估了 DIPK 在临床数据上的适用性。DIPK 准确预测了紫杉醇在病理完全缓解(pCR)组中的更高反应,与残留疾病组相比,证实了 pCR 组对化疗药物的更好反应。我们相信,将 DIPK 整合到临床决策过程中有可能增强癌症患者的个体化治疗策略。